

RECEIVED  
CENTRAL FAX CENTER

MAY 24 2005

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the applications:

Listing of Claims:

Claims 1-3 (canceled)

12  
1. (previously presented) A vector comprising the nucleic acid molecule of claim 100.

3  
2. (previously presented) An isolated host cell comprising the nucleic acid molecule of claim 100.

4  
3. (previously presented) An isolated host cell comprising the nucleic acid molecule of claim 100 operatively linked to a regulatory sequence other than the promoter for a native IL-17 receptor like polypeptide.

15  
4. (previously presented) An isolated host cell modified by transformation or transfection with a regulatory nucleic acid, wherein said regulatory nucleic acid promotes transcription or translation of a nucleic acid comprising the sequence of SEQ ID NO: 1, 4, or 6.

16  
5. (original) The host cell of claim 7 wherein the regulatory nucleic acid sequence is a promoter.

17  
6. (original) The host cell of claim 7 wherein the regulatory nucleic acid is a transcription factor.

5  
7. (previously presented) The host cell of claim 3 that is a eukaryotic cell.

6  
8. (previously presented) The host cell of claim 5 that is a prokaryotic cell.

~~12~~ (previously presented) A process of producing an IL-17 receptor like polypeptide comprising culturing the host cell of claim ~~8~~<sup>7</sup> under suitable conditions to express the polypeptide, and optionally isolating the polypeptide from the culture.

Claim 13 (canceled)

~~14~~ (previously presented) The process of any one of claims ~~12~~<sup>7</sup>, ~~13~~<sup>9</sup> and ~~18~~ wherein the nucleic acid molecule comprises promoter DNA other than the promoter DNA for the native IL-17 receptor like polypeptide operatively linked to the DNA encoding the IL-17 receptor like polypeptide.

Claims 15-58 (canceled)

~~59~~<sup>10</sup> (previously amended) A composition comprising a nucleic acid molecule of claim 100 and a pharmaceutically acceptable formulation agent.

~~60~~<sup>11</sup> (previously presented) A composition of claim 59 wherein said nucleic acid molecule is contained in a viral vector.

~~61~~<sup>12</sup> (previously presented) A viral vector comprising a nucleic acid molecule of claim 100.

Claims 62-73 (canceled)

~~74~~<sup>19</sup> (currently amended) A diagnostic reagent comprising a detectably labeled polynucleotide, encoding the amino acid sequence set out in at least one of SEQ ID NO: 2, SEQ ID NO: 5 or SEQ ID NO: 7 wherein the polynucleotide encodes a polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) amino acids 1 through 560 of SEQ ID NO: 5,

(b) amino acids 1 through 350 of SEQ ID NO: 5, and

(c) amino acids 14 through 350 of SEQ ID NO: 5.

~~75~~<sup>20</sup> (original) The diagnostic reagent of claim 74, wherein said labeled polynucleotide is a first-strand cDNA.

## Claims 76-90 (canceled)

17 91. (previously presented) ~~the~~ An isolated nucleic acid molecule of claim 100 wherein the nucleic acid molecule encodes a polypeptide that induces inflammation.

14 92. (previously presented) ~~the~~ An isolated nucleic acid molecule of claim 100 wherein the nucleic acid molecule encodes a polypeptide that induces myelopoiesis.

## Claims 93-96 (canceled)

9 97. (previously presented) A process of producing an IL-17 receptor like polypeptide comprising culturing the host cell of claim 6 under suitable conditions to express the polypeptide, and optionally isolating the polypeptide from the culture.

16 98. (previously presented) A process of producing an IL-17 receptor like polypeptide comprising culturing the host cell of claim 7 under suitable conditions to express the polypeptide, and optionally isolating the polypeptide from the culture.

99. (canceled)

1 100. (previously presented) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

(a) ~~the~~ a nucleotide sequence comprising nucleotides 50 through 1729 of SEQ ID NO: 4;

(b) ~~the~~ a nucleotide sequence comprising nucleotides 50 through 1099 of SEQ ID NO: 4;

(c) ~~the~~ a nucleotide sequence comprising nucleotides 89 through 1099 of SEQ ID NO: 4;

(d) ~~the~~ a nucleotide sequence encoding a polypeptide comprising amino acids 1 through 560 of SEQ ID NO: 5;

(e) ~~the~~ a nucleotide sequence encoding a polypeptide comprising amino acids 1 through 350 of SEQ ID NO: 5;

(f) ~~the~~ a nucleotide sequence encoding a polypeptide comprising amino acids 14 through 350 of SEQ ID NO: 5;

(g) ~~the~~ a nucleotide sequence encoding a polypeptide having an amino acid sequence that is at least 90 percent identical to amino acids 14 through 350 of SEQ ID NO: 5, wherein the polypeptide binds IL-17; and


(h) ~~the~~ a nucleotide sequence fully complementary to any of (a)-(g).

101. (canceled).

~~21~~ 102. (previously presented) An isolated nucleic acid molecule comprising a nucleotide sequence of the cDNA clone contained in ATCC deposit number PTA-3176. ~~the~~

~~22~~ 103. (previously presented) An isolated nucleic acid molecule comprising a nucleotide sequence, wherein the nucleotide sequence encodes a polypeptide comprising the extracellular domain of an amino acid sequence encoded by the cDNA clone contained in ATCC deposit number PTA-3177.

~~23~~ 104. (previously presented) An isolated nucleic acid molecule comprising a nucleotide sequence of the cDNA clone contained in ATCC deposit number PTA-3178. ~~the~~

~~24~~ 105. (new) An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having an amino acid sequence that is at least 90 percent identical to amino acids 14 through 350 of SEQ ID NO: 5, wherein the polypeptide binds IL-17. 

~~25~~ 106. (new) An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide comprising amino acids 14 through 350 of SEQ ID NO: 5.

~~26~~ 107. (new) An isolated nucleic acid molecule comprising a nucleotide sequence comprising nucleotides 89 through 1099 of SEQ ID NO: 4.